Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Sinovation Ventures

Investor type Venture Capital
Founders Hua Wang Lee Kai-Fu


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 338
Average round size
The average size of a deal this fund participated in
Portfolio companies 255
Rounds per year 24.14
Lead investments 46
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 32
Key employees 17
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Software
  • Artificial Intelligence
  • Internet
  • Mobile
  • Education

Sinovation Ventures appeared to be the VC, which was created in 2009. The main office of represented VC is situated in the Beijing. The fund was located in Asia if to be more exact in China.

The higher amount of exits for fund were in 2018. The fund is constantly included in 13-24 deals per year. Speaking about the real fund results, this VC is 4 percentage points less often commits exit comparing to other organizations. When the investment is from Sinovation Ventures the average startup value is more than 1 billion dollars. Opposing the other organizations, this Sinovation Ventures works on 21 percentage points less the average amount of lead investments. The common things for fund are deals in the range of 10 - 50 millions dollars. The important activity for fund was in 2014. Despite it in 2019 the fund had an activity.

The current fund was established by Hua Wang, Kai-Fu Lee. We also calculated 20 valuable employees in our database.

Among the most popular fund investment industries, there are Education, Machine Learning. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline Bitmain Technologies, Meitu, Vipkid The fund has no exact preference in a number of founders of portfolio startups. When startup sums 5+ of the founder, the probability for it to get the investment is little.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Sinovation Ventures, startups are often financed by Tencent Holdings, Sequoia Capital China, Qiming Venture Partners. The meaningful sponsors for the fund in investment in the same round are Y Combinator, Northern Light Venture Capital, IDG Capital. In the next rounds fund is usually obtained by Northern Light Venture Capital, Innohub Capital, TCL Capital.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Sinovation Ventures:
Typical Co-investors
Sinovation Ventures is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Sinovation Ventures:

Funds with similar focus

Funds from China
Funds with similar focus located in China:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Fande Technology

Data Mining
Industrial Automation
Project Management
30 Dec 2022 Chaoyang, Liaoning, China

Tiger ESOP

Employee Benefits
Human Resources
24 Nov 2022 Haidian, Beijing, China


$1M10 Oct 2022 -


Artificial Intelligence
Internet of Things
$56M23 Sep 2022 Paris, Ile-de-France, France

Guangjing Energy

$4M26 Aug 2022 Foshan, Guangdong, China


Artificial Intelligence
$300M20 Jun 2022 Dongcheng District, Beijing, China


Artificial Intelligence
$300M15 Jun 2022 Dongcheng District, Beijing, China


Industrial Automation
27 Apr 2022 Beijing, Beijing, China

Elixir Clinical Research

$52M26 Apr 2022 Shanghai, Shanghai, China
Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus

– Insilico Medicine announced that it has closed a $255m Series C.
– The financing led by Warburg Pincus, and participated by current investors including Qiming Venture Partners, Pavilion Capital, Eight Roads Ventures, Lilly Asia Ventures, Sinovation Ventures, BOLD Capital Partners, Formic Ventures, Baidu Ventures, and new investors including CPE, OrbiMed, Mirae Asset Capital, B Capital Group, Deerfield Management, Maison Capital, Lake Bleu Capital, President International Development Corporation, Sequoia Capital China and Sage Partners.
– The financing will be used to progress Insilico Medicine’s current therapeutic programs into human clinical trials, initiate multiple new programs for novel and difficult targets, and further develop its AI and drug discovery capabilities.

OnQuality Pharmaceuticals Announces Closing of $35 Million Series A+ Financing

– OnQuality Pharmaceuticals LLC (“OnQuality”), a targeted cancer supportive care company developing medications to address specific side effects and improve the quality of life for patients receiving anti-cancer medications, today announced the closing of its Series A+ financing round securing an additional $20 million in funding. This brings the total amount of capital raised in Series A and A+ to $35 million.
– This financing round included participation from Shiyu Capital, Matrix Partners China, BioTrack Capital, CASH Capital, Sinovation Ventures, FreeS Fund, and additional biotech veterans.
– Proceeds from the financing will support the ongoing Phase II clinical trial of the company’s leading compound OQL011, as well as multiple additional targeted cancer supportive care programs anticipated to enter different phases of clinical development over the next 18 months.
OnQuality also announced the appointment of pharmaceutical executive Michael McCullar, Ph.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Sinovation Ventures?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: